Table 2.

The Associations between CNVs of BCL2L1, MCL1, and NSCLC OS

CNVs	Number of		MST	Univariate analysisa		Multivariate analysisb
	Patients	Death	(months)	HR (95% CI)	P	HR (95% CI)	P
BCL2L1
Overall
Non‐amplification	452	200	65.3	1.00		1.00
Amplification	64	34	45.6	1.41 (0.98–2.03)	0.064	1.62 (1.10–2.40)	0.015
Squamous carcinoma
Non‐amplification	214	89	NA
Amplification	28	17	20.1	1.88 (1.12–3.17)	0.018	1.35 (0.76–2.39)	0.307
Adenocarcinoma
Non‐amplification	221	108	45.3
Amplification	28	16	37.6	1.36 (0.81–2.30)	0.251	1.62 (0.91–2.88)	0.102
MCL1
Overall
Non‐amplification	343	140	66.5	1.00		1.00
Amplification	173	94	46.7	1.29 (0.99–1.67)	0.060	1.39 (1.05–1.84)	0.020
Squamous carcinoma
Non‐amplification	170	69	NA
Amplification	72	37	36.7	1.27 (0.85–1.89)	0.249	1.17 (0.77–1.80)	0.458
Adenocarcinoma
Non‐amplification	158	68	57.2
Amplification	91	56	38.0	1.31 (0.92–1.87)	0.139	1.40 (0.93–2.09)	0.105

CNVs, Copy‐number variation; MST, median survival time; OS, overall survival; HR, hazards ratio; 95% CI, 95% confidence interval.

^aunivariate analysis.

^bAdjusted by age, gender, smoking status, alcohol intake, family history of cancer, histological types, TNM stages, laterality, surgical approach, chemotherapy, radiotherapy, and DNA source.